WO2004014915A1 - Nuevos derivados de cicloalcanodionas procedimiento para su preparación y sus aplicaciones farmacológicas - Google Patents
Nuevos derivados de cicloalcanodionas procedimiento para su preparación y sus aplicaciones farmacológicas Download PDFInfo
- Publication number
- WO2004014915A1 WO2004014915A1 PCT/ES2003/000394 ES0300394W WO2004014915A1 WO 2004014915 A1 WO2004014915 A1 WO 2004014915A1 ES 0300394 W ES0300394 W ES 0300394W WO 2004014915 A1 WO2004014915 A1 WO 2004014915A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- nmr
- compounds
- compound according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 230000000144 pharmacologic effect Effects 0.000 title description 4
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 208000029028 brain injury Diseases 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract description 4
- 230000001575 pathological effect Effects 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 49
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 230000006931 brain damage Effects 0.000 claims description 3
- 231100000874 brain damage Toxicity 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- 206010014498 Embolic stroke Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 74
- 102000005962 receptors Human genes 0.000 abstract description 27
- 108020003175 receptors Proteins 0.000 abstract description 27
- 239000000556 agonist Substances 0.000 abstract description 17
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- 230000000472 traumatic effect Effects 0.000 abstract description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract description 2
- 239000004090 neuroprotective agent Substances 0.000 abstract description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 241000700159 Rattus Species 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 21
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 230000000324 neuroprotective effect Effects 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 210000003710 cerebral cortex Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 8
- 230000002631 hypothermal effect Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000016273 neuron death Effects 0.000 description 6
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000862 serotonergic effect Effects 0.000 description 5
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000699694 Gerbillinae Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000002102 hyperpolarization Effects 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 2
- 229940091173 hydantoin Drugs 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- -1 microgranules Substances 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
- 229960001999 phentolamine Drugs 0.000 description 2
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- MDZDZKKIXUPBSY-UHFFFAOYSA-N 2-(1,2,3,4-tetrahydronaphthalen-1-yl)ethanamine Chemical class C1=CC=C2C(CCN)CCCC2=C1 MDZDZKKIXUPBSY-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- OBLVPZDQQMLQJJ-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethylamino)butyl]-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione Chemical compound C1=CC=C2NC(CNCCCCN3C(=O)N4CCCC4C3=O)=NC2=C1 OBLVPZDQQMLQJJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GZNVXCFAROOETQ-UHFFFAOYSA-N 2-[4-(2-phenoxyethylamino)butyl]-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione Chemical compound O=C1C2CCCN2C(=O)N1CCCCNCCOC1=CC=CC=C1 GZNVXCFAROOETQ-UHFFFAOYSA-N 0.000 description 1
- SOEUUFJBKLEPDF-UHFFFAOYSA-N 2-[4-[(2-methoxyphenyl)methylamino]butyl]-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione Chemical compound COC1=CC=CC=C1CNCCCCN1C(=O)N2CCCC2C1=O SOEUUFJBKLEPDF-UHFFFAOYSA-N 0.000 description 1
- WLBCSRHNYJTWBY-UHFFFAOYSA-N 2-[4-[2-(2-methoxyphenyl)ethylamino]butyl]-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione Chemical compound COC1=CC=CC=C1CCNCCCCN1C(=O)N2CCCC2C1=O WLBCSRHNYJTWBY-UHFFFAOYSA-N 0.000 description 1
- YHZOVSWPDLPWKZ-UHFFFAOYSA-N 2-[4-[3-(2-methoxyphenyl)propylamino]butyl]-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione Chemical compound COC1=CC=CC=C1CCCNCCCCN1C(=O)N2CCCC2C1=O YHZOVSWPDLPWKZ-UHFFFAOYSA-N 0.000 description 1
- APEXDSJBTDQYCA-UHFFFAOYSA-N 2-[4-[4-(2-methoxyphenyl)butylamino]butyl]-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione Chemical compound COC1=CC=CC=C1CCCCNCCCCN1C(=O)N2CCCC2C1=O APEXDSJBTDQYCA-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- JLIKGWPBYNMZNQ-UHFFFAOYSA-N 3-[4-(2-phenoxyethylamino)butyl]-1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1CCCCNCCOC1=CC=CC=C1 JLIKGWPBYNMZNQ-UHFFFAOYSA-N 0.000 description 1
- JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 0 CC(C)(C*(C(C1*2CC*CC1)=O)N*(*)*)C2=O Chemical compound CC(C)(C*(C(C1*2CC*CC1)=O)N*(*)*)C2=O 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MOZPSIXKYJUTKI-UHFFFAOYSA-N GR 113808 Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1 MOZPSIXKYJUTKI-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- ZZJYIKPMDIWRSN-HWBMXIPRSA-N LSM-20934 Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@H]1CN1CC[C@](C(C)(C)C)(O)C[C@H]13 ZZJYIKPMDIWRSN-HWBMXIPRSA-N 0.000 description 1
- 102220506674 MKRN2 opposite strand protein_H26N_mutation Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- MOZPSIXKYJUTKI-RLXJOQACSA-N [1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 1-(tritritiomethyl)indole-3-carboxylate Chemical compound C12=CC=CC=C2N(C([3H])([3H])[3H])C=C1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1 MOZPSIXKYJUTKI-RLXJOQACSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229950006479 butaclamol Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- LXGJPDKYMJJWRB-IERUDJENSA-N cinanserin hydrochloride Chemical compound Cl.CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 LXGJPDKYMJJWRB-IERUDJENSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000009524 hypoxic brain injury Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003723 serotonin 1A agonist Substances 0.000 description 1
- 239000003727 serotonin 1A antagonist Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000004001 thalamic nuclei Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to new chemical compounds, their preparation, pharmaceutical formulations containing them and their use in medicine, particularly the present invention relates to new cycloalkanedione derivatives which are agonists of the serotonin receptor subtype (5-hydroxytryptamine, 5 -HT) 5-HT ⁇ a . Therefore, they are useful in the treatment of pathological conditions for which an agonist of these receptors is indicated.
- the compounds of the present invention are useful as neuroprotective agents, which gives them a special interest in the treatment and prophylaxis of brain damage caused by ischemic or traumatic stroke.
- t-PA tissue plasminogen activator
- the 5-HT ⁇ A receptors whose location is both presynaptic and postsynaptic, are the target of a group of anxiolytic drugs and may also be involved in the actions of certain antidepressant drugs.
- the neuroprotective effect of agonists the 5-HT ⁇ to may be due to different mechanisms, among which hyperpolarization activation of K + channels, inhibiting glutamate release (Matsuyama et al, 1996; Mauler and others, 2001) and the increase in BDNF neurotrophin expression (Galter et al., 2000).
- the present invention refers to new cycloalkanedione derivatives, the process for its preparation and its pharmacological applications.
- said cycloalkanedione derivatives are characterized in that they correspond to the general formula I:
- Ri is selected from the group consisting of H, - (CH 2 ) 3 -,
- R 2 is selected from the group consisting of N, S; n has a value of 0 or 1;
- Z is selected from the group consisting of C2-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl;
- R 3 is selected from the group consisting of H, C1-C10-alkyl, aryl, aralkyl; m has a value of 0 to 2;
- R 4 is selected from the group consisting of O, CH 2 ;
- R5 is selected from the group consisting of:
- R 6 is selected from the group consisting of H, C1-C5-alkyl, Cl-C5-alkoxy, OH, F, Cl, Br, I;
- X is selected from the group consisting of O, S, NH,
- W is selected from the group consisting of S, NH.
- the compounds of formula (I) are those where: Z represents a C2-C10-alkyl group and R 5 is selected from the group consisting of:
- Rx, R 2 , R 3 , n, m, R 4 and R ⁇ are identical to those made previously.
- Rx, R 2 , n, na, R 4 and R 6 are identical to those made previously.
- alkyl groups referred to in the present invention could be linear or branched, and could also be cyclic (for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), or be linear or branched and contain these cyclic moieties.
- alkenyl groups referred to herein The invention is linear (for example 1-propenyl, 2-butenyl) and its isomeric forms.
- alkynyl groups referred to in the present invention are linear (for example 2-butynyl).
- aryl includes any monocyclic aromatic group containing from 5 to 12 carbon atoms, optionally interrupted by one or more heteroatoms selected from N, 0 or S.
- aralkyl refers to an aryl group attached to a previously defined alkyl group, such as benzyl or phenethyl.
- the compounds according to the invention can have several asymmetric carbon atoms and therefore they are presented in various stereochemical forms.
- the compounds according to the invention can also be presented in the form of their salts. In general, its salts may be mentioned with inorganic or organic acids.
- physiologically compatible salts will be preferred. Especially preferred are, for example, salts with hydrochloric acid, bromhydric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, o-toluenesulfonic acid, m-toluenesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, o-naphthalenesulfonic acid, acid m-naphthalenesulfonic acid, p-naphthalenesulfonic acid, acetic acid, propionic acid, lactic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, methyl acid, tartaric acid, citric acid or benzoic acid.
- the compounds with potent agonist action on the 5-HT 1A receptor described in the present invention therefore represent effective products for the treatment of diseases of the central nervous system that include anxiety disorders, various forms of depression and mixed anxiety disorders. depression such as obsessive-compulsive disorders, phobias, bulimia, etc. They are also suitable for the prophylaxis and treatment of neuronal damage in episodes of cerebral infarction, by promoting the survival of cells located in the penumbra area surrounding the ischemic focus.
- the new active products can be transformed in known manner into usual formulations, such as tablets, coated tablets, capsules, pills, granules, microgranules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic excipients or solvents, pharmaceutically adequate.
- the therapeutically active compound must be present respectively at a concentration of approximately
- the compounds described herein are pure 5-HT 1A serotonergic receptor agonists, which has been revealed by suitable functional studies.
- the compounds object of the present invention have a protective effect on neuronal death of apoptotic or necrotic nature induced by serum deprivation or by glutamate in neuronal cultures.
- Rx, R 2 , n, Z, m, R 4 and R 5 in these schemes are identical to those previously made for the products of the invention.
- the intermediates of formula II are obtained by reaction of hydantoin, diketopiperazine or cyclic imide with the appropriate halogenated derivative in the presence of sodium hydride and N, N-dimethylformamide as the reaction solvent, as shown in Scheme III.
- the intermediates of formula IV are obtained by reaction of hydantoin, diketopiperazine or cyclic route with the appropriate halonitrile in the presence of sodium hydride and N, N-dimethylformamide as the reaction solvent, and subsequent catalytic hydrogenation, as represented in the scheme IV.
- the final products have been structurally characterized by IR, NMR and quantitative elemental analysis techniques. For greater ease of handling, when the final product is not crystalline, it is transformed into a pharmaceutically acceptable salt, derived from an inorganic or organic acid.
- the functional nature (agonist / antagonist) of the compounds of the present invention has been studied in vitro by determining the inhibition of the stimulating effect of forskolin on adenylate cyclase in a cell line transfected with the receptor
- 5-HT 1A sometimes comparing the effect obtained with the [ 35 S] GTP ⁇ S fixation test to coronal sections of rat brain as well as the hyperpolarizing effect in the CA ⁇ area of the hippocampus, and also studying, in vivo, the character 5-HT 1A agonist of the new compounds by analyzing typical behavioral effects as well as hypothermia and evaluating the prevention of these effects by the selective antagonist AY-100635.
- the neuroprotective activity of the compounds described in the present invention has been studied, considering their ability to prevent cell death, necrotic or apoptotic, in primary neuronal cultures and studying in vivo the prevention of neuronal death in the CA ⁇ area of the gerbil hippocampus after transient global ischemia as well as the reduction of the volume of cerebral infarction after permanent occlusion of the middle cerebral artery in rats.
- EXAMPLE 8 2- [4- [(Naft-2-yl) methylamino] butyl] -1, 3- dioxoperhydropyrrolo [1,2-c] imidazole, 8. Chromatography: chloroform / methanol, 9: 1. Rto: 25%; mp 125-127 ° C (ethyl acetate). IR (CHC1 3 , cm “1 ): 3417, 1769, 1707.
- C-NMR CDCI 3 , ⁇ : 25.4; 26.2; 27.0; 27.5; 38.4; 45.4; 47.6; 48.5; 63.3; 115.0; 122.0; 139.0; 154.0; 160.8; 174.0.
- EXAMPLE 18 2- [4- [2- (o-Methoxyphenyl) ethylamino] butyl] -1,3-dioxoperhydropyrrolo [1,2-c] imidazole, 18.
- EXAMPLE 21 2- [3- [3- (o-Methoxy enyl) propylamino] propyl] -1,3-dioxoperhydropyrrolo [1,2-c] imidazole, 21.
- the functional nature of the new compounds was initially determined by studying their effect on adenylate cyclase in He-La cells transcribed with the human 5-HT ⁇ receptor, measuring their inhibitory effect on the stimulation of the forskolin-induced enzyme (Table 3 next) .
- the compounds included in this table behaved in all cases as pure agonists, so that values close to 100% inhibition of forskolin-induced activation were achieved.
- the effective concentration 50 (EC 50 ) a concentration that produces 50% inhibition of the increase in forskolin enzyme activity, was in the nanomolar range.
- the action of the new compounds in this test was mediated 1A receptor 5-HT as may be deduced from the blocking of the effect of all compounds studied by the antagonist 5-HT ⁇ A selective AY-100635 (10 "8 M).
- the in vitro agonist character of the new compounds was also assessed in some cases by the [ 35 S] -GTP ⁇ S fixation test to coronal sections of rat brain.
- the results obtained with compounds No. 1 and No. 3, at a concentration of 10 ⁇ M, were essentially similar to those obtained with the 5-HT 1A , 8-OH-DPAT agonist prototype.
- an increase in signal intensity was observed in the hippocampus (CA ⁇ , CA2, CA3 and dentate gyrus), thalamic nuclei, tonsil complex, cortex and in the nuclei of the midbasal hypothalamus.
- the increase in the intensity of the marking in these brain areas was reduced until reaching the control levels when the incubation was carried out in the presence of the molecule under study and the selective 5-HT 1A antagonist AY-100635 (1 ⁇ M).
- the five compounds included in Table 3 also produced hyperpolarization of the potential of the neurons of the hypocampic CAI area. By performing dose-effect curves, it was observed that the action of compounds No. 1 and No. 2 in this assay was potentially indistinguishable from that of the 5-HT 1A , 8-OH-DPAT agonist.
- EXAMPLE 24 Functional characterization in vivo.
- mice All compounds previously characterized in vitro as 5-HT 1A agonists (table 3) were administered subcutaneously to mice to quantify the hypothermia associated with the stimulation of this serotonergic receptor subtype. In all cases, a decrease in mouse rectal temperature was observed, with a variable duration between 30 and 120 minutes. Table 4 below shows the minimum effective doses for each compound studied and the degree of hypothermia achieved at this dose. The maximum hypothermic effect was reached with doses 4-8 times higher than those indicated in this table 4, reaching in some cases temperature drops of 4 ° C. TABLE 4. Test of hypothermia in mice
- EXAMPLE 25 Determination of neuroprotective action in vitro.
- the neuroprotective effect of the compounds considered was studied in experimental models in vitro, using primary rat hippocampus cultures exposed to serum deprivation, a toxic concentration of glutamate, or incubated under hypoxic conditions and absence of glucose.
- compound # 1 was the one that most effectively prevented (37%) the associated damage. Also, this compound presented a neuroprotective effect (> 20%) in the neuronal death model due to exposure of the cultures to a transient situation of hypoxia in the absence of glucose and subsequent incubation in an atmosphere of 5% C0 2 .
- EXAMPLE 26 Determination of neuroprotective action in vivo.
- the neuroprotective action in vivo was evaluated both in the model of transient global ischemia in gerbils and in the model of permanent focal ischemia in rats.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200330451T SI1544201T1 (sl) | 2002-07-31 | 2003-07-29 | Novi derivati cikloalkanodionov, postopek za proizvodnjo le-teh in njihove farmacevtske aplikacije |
CA002492837A CA2492837A1 (en) | 2002-07-31 | 2003-07-29 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications |
UAA200500843A UA79801C2 (en) | 2002-07-31 | 2003-07-29 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications |
MXPA05001245A MXPA05001245A (es) | 2002-07-31 | 2003-07-29 | Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas. |
US10/522,697 US7351732B2 (en) | 2002-07-31 | 2003-07-29 | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications |
EP03784210A EP1544201B1 (en) | 2002-07-31 | 2003-07-29 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications |
AU2003254512A AU2003254512A1 (en) | 2002-07-31 | 2003-07-29 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications |
DE60306534T DE60306534T2 (de) | 2002-07-31 | 2003-07-29 | Neue derivate von cycloalkanodionen, verfahren zu deren herstellung und deren pharmakologische anwendungen |
NZ538489A NZ538489A (en) | 2002-07-31 | 2003-07-29 | Novel derivatives of cycloalkanodiones, method for the production thereof and their pharmacological applications |
JP2004526925A JP2005539017A (ja) | 2002-07-31 | 2003-07-29 | 新規シクロアルカンジオン誘導体、それらの製造方法、及びそれらの医薬適用 |
ES03784210T ES2271673T3 (es) | 2002-07-31 | 2003-07-29 | Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas. |
BR0313375-3A BR0313375A (pt) | 2002-07-31 | 2003-07-29 | Composto de cicloalcanodioanas, método para prepará-lo, composição farmacêutica compreendendo-o e seu uso |
IL16646905A IL166469A0 (en) | 2002-07-31 | 2005-01-24 | Novel derivatives of cycloalcanodiones method for the production thereof and their pharmacological applications |
NO20051068A NO20051068L (no) | 2002-07-31 | 2005-02-25 | Nye derivater av sykloalkandioner, fremgangsmate for fremstilling derav og deres farmakologiske applikasjoner |
CY20061101376T CY1106170T1 (el) | 2002-07-31 | 2006-09-26 | Νεα παραγωγα κυκλοαλκανοδιονων,μεθοδος για την παρασκευη τους και οι φαρμακολογικες τους εφαρμογες |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200201811A ES2199086B1 (es) | 2002-07-31 | 2002-07-31 | Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas. |
ESP200201811 | 2002-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004014915A1 true WO2004014915A1 (es) | 2004-02-19 |
Family
ID=31198114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2003/000394 WO2004014915A1 (es) | 2002-07-31 | 2003-07-29 | Nuevos derivados de cicloalcanodionas procedimiento para su preparación y sus aplicaciones farmacológicas |
Country Status (23)
Country | Link |
---|---|
US (1) | US7351732B2 (es) |
EP (1) | EP1544201B1 (es) |
JP (1) | JP2005539017A (es) |
KR (1) | KR20050042471A (es) |
CN (2) | CN100422185C (es) |
AT (1) | ATE331717T1 (es) |
AU (1) | AU2003254512A1 (es) |
BR (1) | BR0313375A (es) |
CA (1) | CA2492837A1 (es) |
CY (1) | CY1106170T1 (es) |
DE (1) | DE60306534T2 (es) |
DK (1) | DK1544201T3 (es) |
ES (2) | ES2199086B1 (es) |
IL (1) | IL166469A0 (es) |
MX (1) | MXPA05001245A (es) |
NO (1) | NO20051068L (es) |
NZ (1) | NZ538489A (es) |
PL (1) | PL373644A1 (es) |
PT (1) | PT1544201E (es) |
RU (1) | RU2322445C2 (es) |
UA (1) | UA79801C2 (es) |
WO (1) | WO2004014915A1 (es) |
ZA (1) | ZA200500784B (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005075480A1 (en) * | 2004-01-30 | 2005-08-18 | Schwarz Pharma S.L. | Diaza- or thiazadione derivatives with neuroprotective activity |
US7351732B2 (en) | 2002-07-31 | 2008-04-01 | Schwarz Pharma S.L. | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications |
EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008015538A2 (en) * | 2006-07-31 | 2008-02-07 | Schwarz Pharma S.L. | Use of diaza- and thiaza-cycloalkanediones for preventing and/or treating pain and /or migraine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2052829T3 (es) * | 1988-07-28 | 1994-07-16 | Bayer Ag | Aminoetiltetralinas substituidas asi como sus analogos heterociclicos. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4055410A (en) * | 1976-03-15 | 1977-10-25 | E. I. Du Pont De Nemours And Company | Substituted bromo- or chloroacetamide herbicides |
DE2862059D1 (en) * | 1977-12-29 | 1982-11-11 | Synthelabo | Thiazolidinedione-2,4 derivatives, their preparation and pharmaceutical applications |
EP0510691B1 (en) * | 1991-04-26 | 2004-11-03 | Osaka Bioscience Institute | DNA coding for human cell surface antigen |
TW288010B (es) * | 1992-03-05 | 1996-10-11 | Pfizer | |
AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
AU3079295A (en) | 1994-09-01 | 1996-03-22 | Universidad Complutense De Madrid | New arylpiperazine derivatives |
ES2082727B1 (es) | 1994-09-01 | 1996-10-16 | Univ Madrid Complutense | Nuevos derivados de arilpiperazinas. |
ES2094690B1 (es) | 1994-11-22 | 1997-08-01 | Univ Madrid Complutense | Nuevos derivados de imida-piperazinas. |
ES2109190B1 (es) | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
ES2129370B1 (es) | 1997-09-23 | 2000-03-01 | Univ Madrid Complutense | Procedimiento para la obtencion del 2-(4-(4-(m-etilsulfonamidofenil)p iperazin-1-il(butil)-1,3-dioxoperhidropirrolo)1,2-c(imidazol |
US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
ES2154605B1 (es) | 1999-09-14 | 2001-11-16 | Univ Madrid Complutense | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 |
DE10148425A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Chromane |
ES2199086B1 (es) | 2002-07-31 | 2005-06-01 | Cepa Schwarz Pharma Sl | Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas. |
ES2238015B1 (es) | 2004-01-30 | 2006-11-01 | Cepa Schwarz Pharma, S.L. | Derivados de cicloalcanodionas con actividad neuroprotectora. |
EP1674103A1 (en) | 2004-12-27 | 2006-06-28 | Cepa Schwarz Pharma s.l. | Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands |
-
2002
- 2002-07-31 ES ES200201811A patent/ES2199086B1/es not_active Expired - Fee Related
-
2003
- 2003-07-29 JP JP2004526925A patent/JP2005539017A/ja active Pending
- 2003-07-29 AT AT03784210T patent/ATE331717T1/de not_active IP Right Cessation
- 2003-07-29 US US10/522,697 patent/US7351732B2/en not_active Expired - Fee Related
- 2003-07-29 CN CNB038183390A patent/CN100422185C/zh not_active Expired - Fee Related
- 2003-07-29 AU AU2003254512A patent/AU2003254512A1/en not_active Abandoned
- 2003-07-29 PL PL03373644A patent/PL373644A1/xx not_active Application Discontinuation
- 2003-07-29 KR KR1020057001543A patent/KR20050042471A/ko not_active Application Discontinuation
- 2003-07-29 DE DE60306534T patent/DE60306534T2/de not_active Expired - Fee Related
- 2003-07-29 NZ NZ538489A patent/NZ538489A/en unknown
- 2003-07-29 RU RU2005102821/04A patent/RU2322445C2/ru not_active IP Right Cessation
- 2003-07-29 CN CNA2007101694908A patent/CN101172977A/zh active Pending
- 2003-07-29 PT PT03784210T patent/PT1544201E/pt unknown
- 2003-07-29 EP EP03784210A patent/EP1544201B1/en not_active Expired - Lifetime
- 2003-07-29 CA CA002492837A patent/CA2492837A1/en not_active Abandoned
- 2003-07-29 MX MXPA05001245A patent/MXPA05001245A/es active IP Right Grant
- 2003-07-29 WO PCT/ES2003/000394 patent/WO2004014915A1/es active IP Right Grant
- 2003-07-29 BR BR0313375-3A patent/BR0313375A/pt not_active IP Right Cessation
- 2003-07-29 ES ES03784210T patent/ES2271673T3/es not_active Expired - Lifetime
- 2003-07-29 DK DK03784210T patent/DK1544201T3/da active
- 2003-07-29 UA UAA200500843A patent/UA79801C2/uk unknown
-
2005
- 2005-01-24 IL IL16646905A patent/IL166469A0/xx unknown
- 2005-01-25 ZA ZA200500784A patent/ZA200500784B/xx unknown
- 2005-02-25 NO NO20051068A patent/NO20051068L/no not_active Application Discontinuation
-
2006
- 2006-09-26 CY CY20061101376T patent/CY1106170T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2052829T3 (es) * | 1988-07-28 | 1994-07-16 | Bayer Ag | Aminoetiltetralinas substituidas asi como sus analogos heterociclicos. |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7351732B2 (en) | 2002-07-31 | 2008-04-01 | Schwarz Pharma S.L. | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications |
WO2005075480A1 (en) * | 2004-01-30 | 2005-08-18 | Schwarz Pharma S.L. | Diaza- or thiazadione derivatives with neuroprotective activity |
JP2007519679A (ja) * | 2004-01-30 | 2007-07-19 | シュワルツ・ファルマ・ソシエダド・リミタダ | 神経保護活性を有するジアザ−またはチアザジオン誘導体 |
EA009280B1 (ru) * | 2004-01-30 | 2007-12-28 | Шварц Фарма, С.Л. | Циклоалкандионовые производные с нейропротективной активностью |
EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
WO2011076708A1 (en) | 2009-12-22 | 2011-06-30 | Peter Gmeiner | New aminotetraline derivatives |
Also Published As
Publication number | Publication date |
---|---|
MXPA05001245A (es) | 2005-09-12 |
US20050250777A1 (en) | 2005-11-10 |
JP2005539017A (ja) | 2005-12-22 |
US7351732B2 (en) | 2008-04-01 |
ATE331717T1 (de) | 2006-07-15 |
CA2492837A1 (en) | 2004-02-19 |
IL166469A0 (en) | 2006-01-15 |
CN100422185C (zh) | 2008-10-01 |
DE60306534D1 (de) | 2006-08-10 |
ES2199086A1 (es) | 2004-02-01 |
CN101172977A (zh) | 2008-05-07 |
BR0313375A (pt) | 2005-06-21 |
RU2322445C2 (ru) | 2008-04-20 |
PL373644A1 (en) | 2005-09-05 |
EP1544201B1 (en) | 2006-06-28 |
DE60306534T2 (de) | 2007-04-19 |
UA79801C2 (en) | 2007-07-25 |
KR20050042471A (ko) | 2005-05-09 |
NO20051068L (no) | 2005-02-25 |
NZ538489A (en) | 2006-09-29 |
CN1671708A (zh) | 2005-09-21 |
DK1544201T3 (da) | 2006-10-30 |
PT1544201E (pt) | 2006-11-30 |
ZA200500784B (en) | 2006-08-30 |
ES2199086B1 (es) | 2005-06-01 |
AU2003254512A1 (en) | 2004-02-25 |
CY1106170T1 (el) | 2011-06-08 |
ES2271673T3 (es) | 2007-04-16 |
RU2005102821A (ru) | 2005-10-10 |
EP1544201A1 (en) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102153562B (zh) | 螺-吲哚酮化合物及其作为治疗剂的用途 | |
JP4377942B2 (ja) | テトラヒドロインドロン及びテトラヒドロインダゾロン誘導体 | |
US9187474B2 (en) | Raf inhibitor compounds | |
ES2694860T3 (es) | 2-Amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1 | |
CN105175433A (zh) | 螺羟吲哚化合物及其作为治疗剂的用途 | |
BR112013018602A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico | |
JPH09500908A (ja) | ジヒドロピラゾロピロール類 | |
JP2010518026A (ja) | ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物 | |
JP2020512337A (ja) | 二環式ヘテロアリール誘導体ならびにその調製および使用 | |
CA2927830A1 (en) | Quinazolinone and isoquinolinone derivative | |
US10316038B2 (en) | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | |
CZ113692A3 (en) | Quinoxalines, process of their preparation and their use | |
SK2852000A3 (en) | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT1Bì (54) ANTAGONIST OR PARTIAL AGONIST | |
US10501466B2 (en) | WDR5 inhibitors and modulators | |
AU2002367323A8 (en) | Benzothieno (3,2- | |
US20150352082A1 (en) | Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases | |
ES2271673T3 (es) | Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas. | |
Sun et al. | Design, synthesis of 8-alkoxy-5, 6-dihydro-[1, 2, 4] triazino [4, 3-a] quinolin-1-ones with anticonvulsant activity | |
US20170174633A1 (en) | Pyrazole compounds selective for neurotensin 2 receptor | |
JP2021512942A (ja) | トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびmGlu5受容体のモジュレータとしてのそれらの使用 | |
ES2866324T3 (es) | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria | |
JPWO2002079204A1 (ja) | 8−チアゾリル[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体 | |
JP7308911B2 (ja) | ニューロンヒスタミン受容体-3アンタゴニストとしての化合物およびその使用 | |
EA009280B1 (ru) | Циклоалкандионовые производные с нейропротективной активностью | |
CA3233231A1 (en) | Irhom2 inhibitors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2492837 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 166469 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/00784 Country of ref document: ZA Ref document number: 200500784 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10522697 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057001543 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/001245 Country of ref document: MX Ref document number: 373644 Country of ref document: PL Ref document number: 2004526925 Country of ref document: JP Ref document number: 20038183390 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005102821 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003784210 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003254512 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 538489 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057001543 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003784210 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003784210 Country of ref document: EP |